June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Author Affiliations & Notes
  • Davine Sijnave
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Karolien Hollanders
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Tine Van Bergen
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Sarah Van de Velde
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Evelien Vandewalle
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Lieve Moons
    Department of Biology, KULeuven, Leuven, Belgium
  • Dirk Leysen
    Amakem Therapeutics, Diepenbeek, Belgium
  • Ingeborg Stalmans
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Footnotes
    Commercial Relationships Davine Sijnave, Amakem therapeutics (F); Karolien Hollanders, None; Tine Van Bergen, None; Sarah Van de Velde, Amakem Therapeutics (F); Evelien Vandewalle, None; Lieve Moons, None; Dirk Leysen, Amakem NV (E); Ingeborg Stalmans, Amakem (F), Amakem (C), Amakem (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5225. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Davine Sijnave, Karolien Hollanders, Tine Van Bergen, Sarah Van de Velde, Evelien Vandewalle, Lieve Moons, Dirk Leysen, Ingeborg Stalmans; THE EFFECT OF LOCAL ROCK-INHIBITION ON CORNEAL SCARRING AFTER ALKALI BURN INJURY. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5225.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The aim of this study was to investigate the efficacy of a local ROCK-inhibitor AMA0526 (Amakem NV) on corneal scarring induced by alkali burn in an in vivo mouse model.

Methods: Male Swiss mice (aged 6-8 weeks) were divided randomly into 3 groups after chemical cauterization of the cornea by alkali. Topical treatment was initiated after the injury and given once daily. The first group received 0.1% of the local ROCK-inhibitor AMA0526 versus Vehicle (experimental group 1), the second group was treated with bevacizumab (Avastin; anti-VEGF) versus AMA0526 (experimental group 2) and the third group was used as control and received no treatment. Corneal opacity and corneal neovascularization were graded every other day according to a 0-4 scoring. Blood vessel formation, collagen deposition and macrophage corneal infiltration after injury were assessed and compared by immunohistochemistry on day 7 and 14 after alkali burn.

Results: Both corneal opacity and neovascularization were reduced after AMA0526 treatment compared to the vehicle treated eye (p<0.05 at day 5, 7 and 9). Infiltration of inflammatory cells (p=0.000056; 22.27% reduction) and blood vessel formation (p=0.00208; 42.26% reduction) were significantly inhibited at day 7. No clear reduction of fibrosis was seen. No significant differences could be observed in corneal neovascularization and immunohistological analyses in the experimental group 2. However, AMA0526 treated mice showed significant reduced corneal opacity compared to mice treated with bevacizumab.

Conclusions: Targeting ROCK with a local ROCK inhibitor, AMA0526 is efficacious in improving and preventing corneal opacity and neovascularization after alkali burn. The results presented indicate that ROCK is an appealing target to treat and prevent corneal scarring and neovascularization and illustrate the potential therapeutic benefits of the local ROCK inhibitor, AMA0526.

Keywords: 480 cornea: basic science • 765 wound healing • 609 neovascularization  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.